ABSTRACT
AIM:
The aim of this study was to evaluate whether the neoadjuvant use of the dexamethasone (DEX) plus octreotide (OCT) regimen can improve the direct anticancer effects of docetaxel (DOC) in the TRAMP-C1 prostate cancer model.
MATERIALS AND METHODS:
TRAMP-C1 cells were first characterized for the expression of SSTR1-5 and then were inoculated onto the femur of C57Bl mice. Investigation protocols employed TRAMP-C1 cell proliferation and invasion assays, analysis of radiographic images of the bone lesions and overall survival of the diseased animals.
RESULTS:
The triple combination treatment scheme showed significant anticancer effects, in both proliferation and invasion assays, compared to any single agent treatment scheme. DOC treatment following the neoadjuvant administration of DEX plus OCT regimen improved significantly the anticancer effects both on the grading of the bone lesions and on the overall survival of the diseased animals.
CONCLUSION:
Our data suggest that the neoadjuvant administration of DEX plus OCT regimen can improve the anticancer effects of DOC on the TRAMP-C1 model.
Dexamethasone plus octreotide regimen increases anticancer effects of docetaxel on TRAMP-C1 prostate cancer model
Riferimento:
In Vivo. 2012 Jan-Feb;26(1):75-86.
Autori:
Dalezis P, Geromichalos GD, Trafalis DT, Pissimissis N, Panagiotopoulou D, Galaktidou G, Papageorgiou E, Papageorgiou A, Daifoti Z, Lymperi M, Koutsilieris M.
Fonte:
In Vivo. 2012 Jan-Feb;26(1):75-86.
Anno:
2012
Azione:
Il regime di somministrazione neoadiuvante di desametasone (DEX) più octreotide (OCT) può migliorare gli effetti antitumorali del docetaxel (DOC) sul modello di cancro alla prostata TRAMP-C1.
Target:
Desametasone-octreotide/cancro alla prostata.
Sostanze: